Rand Sutherland

Dr. Sutherland is a physician-scientist focused on developing novel treatments for patients with rare and difficult-to-treat conditions, across multiple therapeutic areas. He is currently Chief Executive Officer of Seeker Biologics, a privately-held biotechnology company discovering and developing targeted therapies for the treatment of autoimmune diseases. Prior to joining Seeker, Dr. Sutherland was President of Translate Bio, leading teams responsible for developing the company’s mRNA technology in cystic fibrosis and other rare diseases, until its acquisition in 2021. Prior to joining Translate Bio, he served in various research, development and medical affairs roles at Sanofi, including as Global Head of Rare Diseases Development, where he and his colleagues designed and executed innovative clinical development programs for novel therapies in lysosomal storage diseases, rare neurological conditions, and rare blood disorders. Dr. Sutherland also serves as an independent director of Krystal Biotech.